This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter revenue up 36.3% year on year, but loss continues
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts less than Nifty Microcap 250 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis for the quarter ended September 30, 2026, revenue was Rs 4342 million versus Rs 3185 million a year earlier, up 36.3%, while profit after tax was a loss of Rs 61 million versus a loss of Rs 349 million. Operating profit before other income, interest, depreciation and tax margin rose from 2.3% to 10.3%. The auditor flagged uncertainty over environmental compliance, with no provision for Rs 174.5 million in compensation.
Strong sales growth and better operating performance are positive, but the continuing loss and environmental exposure may keep share price volatile.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹434.2 Cr | ₹318.5 Cr | +36.3% |
| Operating profit | −₹10.20 Cr | −₹48.90 Cr | loss narrowed |
| Profit after tax | −₹6.10 Cr | −₹34.90 Cr | loss narrowed |
| EBITDA margin | 10.3% | 2.3% | +8.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.